BVXV News and Press, BiondVax Pharmaceuticals Ltd. From 06/05/23

Broad-based collaboration with Max Planck and University Medical Center Gottingen yields attractive anti-IL-17 VHH antibodies (NanoAbs); includes exclusive worldwide license for all potential indications, beginning with psoriasis. BiondVax to lead development and commercialization of Nano...

Biotechnology innovator BiondVax Pharmaceuticals is dedicated to developing nanosized antibody (NanoAb) treatment BiondVax is also leveraging its team experience in preclinical stage to Phase 3 clinical trial product development to generate new revenues by offering cGMP contract development and...

Researchers from the UCLA Jonsson Comprehensive Cancer Center may have come up with a strategy that would allow them to eliminate the side effects associated with immunotherapy.  Immunotherapy is a cancer treatment that leverages a patient’s own immune system to fight and kill cancer ...

Analysts at Aegis Capital Corp. continue to recommend shares of the company with a Buy rating and a $70 target price Data from pre-clinical trial indicate that BiondVax’s NanoAb may effectively serve as both a therapeutic and protective prophylactic drug, further enhancing its value prop...

Biotechnology innovator BiondVax Pharmaceuticals recently provided a business update and published full-year financial results for the period ended December 31, 2022 Achievements realized to date leave CEO Amir Reichman optimistic about the company’s growth potential and ability to deliv...

Multiple sclerosis is a debilitating disease that damages the brain and spinal cord and often causes life-changing symptoms. It is an autoimmune disorder that occurs when the immune system mistakes the body’s tissues as hostile and begins to attack the brain and spinal cord. This causes ...

BiondVax (NASDAQ: BVXV) is a biotechnology company focused on developing, manufacturing and commercializing innovative immunotherapeutic products primarily for the treatment of infectious and autoimmune diseases. The company aims to complement its core focus, nanosized antibody (“NanoAb&#...

Infectious diseases are illnesses caused by organisms such as viruses, bacteria, parasites or fungi. Common infectious diseases include malaria, measles, salmonella, HIV, the flu, coronavirus, tuberculosis and malaria. Infectious illnesses are usually transmitted from one individual to another w...

BiondVax Pharmaceuticals (NASDAQ: BVXV) , a biotechnology company focused on developing, manufacturing and commercializing innovative immunotherapeutic products primarily for the treatment of infectious and autoimmune diseases, is reporting its financial results for the first quarter ended March ...

2023-05-15 17:56:10 ET Biondvax Pharmaceuticals press release ( NASDAQ: BVXV ): Q1 GAAP EPS of $0.00 beats by $0.73 . As of March 31, 2023, BiondVax had cash and cash equivalents of $10.9 million as compared to $14.2 million as of December 31, 2022. The decrease i...